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Background. Clinical studies investigating topical hemostatic agents have not used standardized
definitions for intraoperative bleeding. The Food and Drug Administration has recently sought use of a
validated, clinician-reported scale to standardized bleeding sites in these clinical studies. The intent of a
scale is to reduce patient risk, generate labeling claims, and allow comparisons among study results. We
describe the development and validation of an intraoperative bleeding severity scale.
Methods. A concept phase defined the framework of the scale. A feasibility and validation phase
investigated the usability, clarity, relevance, and reliability (ie, intra- and interobserver concordance)
among surgeons and surgical specialties as required by the Food and Drug Administration for the
validation of a clinician-reported scale. Data were collected using an online tool. A total of 144 surgeons
participated in the 3 phases.
Results. The scale developed during the concept phase achieved an average intraobserver concordance of
0.97 and an interobserver concordance of 0.89 in the feasibility phase (N = 33); a concordance of 1.0 is
perfect. The scale was refined and then achieved an average intraobserver concordance of 0.98 and an
interobserver concordance of 0.91 in the validation phase with unanimous agreement by surgeons from
multiple surgical specialties that the scale can be implemented into clinical studies (N = 102).
Conclusion. This study validated an intraoperative bleeding severity scale for use in clinical studies
investigating hemostatic agents. The scale was usable, clear, and clinically relevant with excellent
reliability. The scale fulfills requirements of the Food and Drug Administration for a clinician-reported
scale and can be used to generate clinically meaningful labeling claims. (Surgery 2016;j:j-j.)From Baxter Healthcare Corporation,a Deerfield, IL; BioMedCom Partners, Inc,b New York, NY; the
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x.doi.org/10.1016/j.surg.2016.09.022IN THE PAST CENTURY, surgical hemostasis has become
a central tenet to the advancement of surgery.1
The use of hemostatic agents is a standard-of-care
treatment in many surgical specialties2-6 with
increased use in major surgeries.7,8 Inadequate or
incomplete hemostasis significantly increases the
risk of perioperative morbidity and mortality,9,10
significantly increases health care costs and
resource use,11-14 and is worsened by the use of an-
tiplatelet and antithrombotic agents.15-17 The need
for hemostasis has led to the development of
several topical hemostatic agents.
Clinical studies investigating topical hemostatic
agents have not used standardized definitions or
classifications for intraoperative bleeding severity
or hemostasis,18,19 in part due to the lack ofSURGERY 1
Table I. Criteria for a clinician-reported scale (CRS) based on the Food and Drug Administration’s
essential elements and criteria to evaluate a CRS
Element Criteria definition
Ability to detect change Clinicians’ scores change in response to changes of the intended measurement
concept across the entire range that is clinically expected.
Clarity CRS is reported as clear by a large segment of the user population.
Construct validity Items and domains of a CRS are appropriate and comprehensive relative to its
intended measurement concept, population, and use.
Relevance CRS is reported as relevant by a large segment of the user population.
Repeatability CRS use provides the ability to yield consistent, repeatable results from the same
clinician (ie, intraobserver).
Reproducibility CRS use provides the ability to yield consistent, reproducible results from multiple
clinicians (ie, interobserver).
Response range Clinicians use both ends of the scale, response choices apply, and distribution is not
highly skewed.
Usability Clinicians are able to use the scale, as well as comprehend, retain, and accurately
follow instructions.
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2 Lewis et alconsensus in defining bleeding severity and in part
due to the lack of requirement to do so. As a result,
the labeling claims of hemostatic agents lack differ-
entiation (eg, the appropriate severity or type of
bleeding to be treated) (Online Supplement:
eTable I). The generic labeling claims further
impede surgeons’ selection of the appropriate
agent, conceal meaningful clinical differences,
and lead to inefficiencies in surgery.8
The use of a validated bleeding severity scale
can establish standardized inclusion and exclusion
criteria in a clinical study so that appropriate
labeling claims can be generated. Furthermore,
the use of standardized criteria ensures that
patients are not subject to undue risks (eg, failed,
delayed, or use of inappropriate treatments). With
standardized criteria, patient and clinical study
outcomes can also be compared to determine
relative effectiveness.
Given these benefits, the United States Food
and Drug Administration (FDA) now requires the
use of a validated bleeding severity scale in clinical
studies investigating hemostatic agents. Since no
intraoperative bleeding severity scale has been
validated for open surgical procedures and is
applicable to multiple surgical specialties, the
objective of this study was to develop and validate
a clinician-reported scale (CRS) for intraoperative
bleeding severity for use in clinical studies of
hemostatic agents.
METHODS
The FDA provides guidance for the creation,
development, and validation of a CRS.20 Within
this guidance, there are specific criteria that
must be fulfilled for acceptability and validation(Table I). These criteria were addressed
throughout the development and validation in
which surgeons from different surgical specialties
developed and applied a scale to the full spectrum
of bleeding as depicted in several videos.
Bleeding videos. Clinical videos lack standard-
ized quality and the ability to predict the level of
bleeding and measure the rate of blood loss;
therefore, an animal model was required to create
the videos. All animal activities were performed
according to the Guide for the Care and Use of
Laboratory Animals and the United States Animal
Welfare Act in an institution accredited by the
Association for Assessment and Accreditation of
Laboratory Animal Care International following
Institutional Animal Care and Use Committee
approval.
Pigs were selected due to their anatomical size
and organ structure, which are similar to that of
humans.21 Eight male, domestic pigs were used to
create videos representing the full range of blood
loss across multiple surgical specialties and coagu-
lopathic conditions (Fig 1). Male pigs were used to
avoid coagulation differences related to estrus. No
adjunctive hemostatic agents were used in the
videos (eg, oxidized cellulose, collagen, fibrin
glue, etc).
For each bleeding model, the rate of blood loss
was measured by collecting blood from each lesion
with preweighed gauze for 6 seconds then calcu-
lating the difference and multiplying by 10 to
obtain a rate in milliliters per minute, where 1 g of
blood loss equated to 1 mL.
Videos were then selected based on representa-
tive rates of intraoperative blood loss, suitable
cinematic quality, and clinical relevance (Online
Fig 1. Bleeding severity models. Various depictions of clinically relevant bleeding performed in a porcine animal
model; specifically, (A) aortotomy closure site, (B) untreated, superficial hepatic abrasion, (C) untreated, deep nephric
abrasion, (D) untreated intramammary dissection with vascular rupture, (E) untreated hepatic laceration, (F) un-
treated, superficial nephric abrasion, (G) untreated partial cystotectomy, (H) superficial, cardiac laceration, (I) un-
treated partial hepatectomy, and (J) untreated, supra-renal abdominal aortotomy.
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to be 15 seconds.
Concept, feasibility, and validation study
phases. The development and validation of the
scale had 3 study phases: concept, feasibility, and
validation. During each phase, surgeons were
recruited based on the anatomic cavity in which
he or she performs surgery according to American
Medical Association surgical specialties. Surgeons
were identified based on demonstrated involve-
ment or interest in clinical studies of hemostatic
agents. Surgeons were not selected based on pre-
vious consultancy agreements, product usage, or
industry affiliations. Once recruited, surgeons
were only allowed to participate in one of the
phases to avoid participant overlap and creation
bias. Three surgeons from the concept phase,
however, were selected as advisors and participated
throughout the validation (P.E.S., E.L., A.D.). All
surgeons were recruited by BioMedCom Partners,
Inc (New York, NY).
Concept study phase. This phase defined the
conceptual framework and the intended use of
the scale. A minimum of 3 surgeons from the 3
surgical cavities, 9 surgeons total, were recruited to
participate. Each surgeon was board certified and a
recognized leader within their field of surgery.
This study phase was performed face-to-face, dur-
ing which qualitative data were collected.
Feasibility study phase. This phase investigated the
construct validity, ability to detect change, clarity,
relevance, and response range of the scale devel-
oped during the concept phase and determined
the videos needed for the validation phase. A
minimum of 10 surgeons from each of the 3
surgical cavities, 30 surgeons total, were recruited
to participate. Each surgeon was board certified
and had a minimum of 5 years of postgraduate
surgical experience. This study phase was per-
formed face-to-face, during which quantitativeand qualitative data were collected via an online
data collection tool. The online data collection
tool was designed and implemented by Bio-
MedCom Partners, Inc.
Surgeons were didactically trained on the use of
the scale and provided videos depicting different
severities of bleeding specific to their own surgical
cavity. Participants then individually used the scale
to assess 15 videos relevant to their surgical cavity,
after which they graded 15 additional videos from
each of the other 2 surgical cavities. Each set of 15
videos contained 10 unique videos, of which 5 were
repeated as duplicate videos. The 10 unique videos
were used to assess interobserver agreement. The 5
duplicate videos were used to assess intraobserver
agreement.
Validation study phase. This phase obtained statis-
tically meaningful inter- and intraobserver agree-
ment data using the scale and additional
observational data supporting the scale’s usability,
clarity, and relevance. A minimum of 30 surgeons
from each of the 3 surgical cavities, 90 surgeons
total, were recruited to participate. Each surgeon
was board certified and had a minimum of 5 years of
postgraduate surgical experience. This study phase
was performed entirely through the online data
collection tool used in the feasibility phase, in which
quantitative and qualitative data were collected.
Surgeons were self-trained on the scale through
visual presentation and training videos of each
level of severity. Surgeons then used the scale to
grade 17 videos not specifically related to their
surgical cavity. Of the 17 videos, the first 2 videos
were not analyzed, the next 10 videos were unique,
and the last 5 videos were repeats. The first 2
videos allowed familiarization with the online tool,
video and question format, and data entry. The 10
unique videos were to assess interobserver agree-
ment. The 5 duplicate videos were to assess intra-
observer agreement.
Table II. Surgeon participants
Concept (N = 9) Feasibility (N = 33) Validation (N = 102)
Per surgical specialty*
Bariatric — 3 (9.1) 1 (1.0)
Cardiac 3 (33.3) 10 (30.3) 24 (23.5)
Colorectal 1 (11.1) 1 (3.0) 2 (2.0)
General 1 (11.1) 3 (9.1) 18 (17.7)
Gynecologic oncology — 1 (3.0) 8 (7.8)
Hepatobiliary 1 (11.1) 4 (12.1) 2 (2.0)
Obstetrics and gynecology — — 8 (7.8)
Pulmonary — — —
Thoracic — — 3 (2.9)
Trauma — 1 (3.0) 13 (12.8)
Urology 3 (33.3) 9 (27.3) 16 (15.7)
Vascular — 1 (3.0) 7 (6.9)
Hospital setting
Academic 7 (77.8) 26 (78.8) 65 (63.7)
Academic/nonprofit 1 (11.1) — 5 (4.9)
Academic/private — — 1 (1.0)
Academic/nonprofit/private — — 3 (2.9)
Nonprofit — 2 (6.1) 7 (6.9)
Private 1 (11.1) 4 (12.1) 19 (18.6)
Private/nonprofit — 1 (3.0) 2 (2.0)
*Neurological, Ophthalmic, Oral and maxillofacial, Orthopedic, Otolaryngology, Pediatric, Plastic, and Maxillofacial specialties were excluded.
Surgeon sample size and backgrounds per study phase. Surgeon involvement was essential for scale acceptability, credibility, clarity, relevance, and usabil-
ity. Data are presented as number (percent).
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and among surgical cavities (ie, interobserver
agreement), and agreement within a surgeon and
within a surgical cavity (ie, intraobserver agree-
ment) was investigated. Interobserver agreement
measures reproducibility, and intraobserver agree-
ment measures repeatability of using a scale. Inter-
and intraobserver agreement was analyzed using
the Kendall’s coefficient of concordance (Ken-
dall’s W) statistic. A Kendall’s W of $0.7 is
considered as “acceptable,” $0.8 as “appreciable,”
$0.9 as “excellent,” and 1.0 as “perfect” concor-
dance.22,23 Box plots were used to present intraob-
server Kendall’s W statistics. Qualitative data were
summarized using frequencies and percentages.
The sample size of the validation phase was
based on an experimental power calculation after
the feasibility phase, in which a sample size of 90
subjects assessing 10 videos achieves >80% power
to detect a Kendall’s W of 0.80 for interobserver
agreement, and assessing 5 videos twice achieves
>80% power to detect a Kendall’s W of 0.80 for
intraobserver agreement.
RESULTS
Concept study phase. Nine surgeons partici-
pated (Table II). The average years of practice
was 15 (standard deviation = 6.0). All surgeonsreported using hemostatic agents in practice. The
surgeons critically assessed the possible inclusion
items and domains for a scale, which were then
narrowed to those deemed most relevant (ie,
anatomical appearance, intervention, qualitative
description, visual appearance, and visually esti-
mated rate of blood loss). The surgeons then
defined the items and domains according to a
quantitative structure, where grade 0 was “no
bleeding” and grade 4 was “life-threatening
bleeding.”
Feasibility study phase. Thirty-three surgeons
participated (Table II). The average years of prac-
tice was 16.6 (7.6). All surgeons reported having
used hemostatic agents.
All surgeons deemed a validated scale necessary
for clinical studies, and 87.9% (n = 29) deemed it
necessary for making labeling claims. Thirty-two
surgeons (97.0%) agreed that the scale can be im-
plemented for use in a clinical study. Thirty sur-
geons agreed that the scale was either “very”
(n = 5, 15.2%) or “mostly” (n = 25, 75.8%) self-
explanatory, while 3 (9.1%) surgeons held that it
was “not really,” and none felt that it was “not at
all” self-explanatory. All surgeons agreed that the
scale reflected the range of bleeding site sizes
and severities expected in clinical practice. Sur-
geon scores detected change across the videos,
Table III. Response range and frequency of bleeding scores
Bleeding severity grade Abdominal cavity videos Pelvic cavity videos Thoracic cavity videos
Video 1, bleed rate 22.8 mL/min 5.1 mL/min 19.7 mL/min
0 0 (0) 0 (0) 1 (3.0)
1 1 (3.0) 19 (57.6) 1 (3.0)
2 21 (63.6) 12 (36.4) 3 (9.1)
3 10 (30.3) 2 (6.1) 25 (75.8)
4 1 (3.0) 0 (0) 3 (9.1)
Video 2, bleed rate 0.6 mL/min 16.5 mL/min 14.6 mL/min
0 11 (33.3) 0 (0) 0 (0)
1 21 (63.7) 0 (0) 1 (3.0)
2 1 (3.0) 13 (39.4) 12 (36.4)
3 0 (0) 20 (60.6) 17 (51.5)
4 0 (0) 0 (0) 3 (9.1)
Video 3, bleed rate 6.4 mL/min 0.7 mL/min 1.6 mL/min
0 0 (0) 32 (97.0) 1 (3.0)
1 1 (3.0) 1 (3.0) 29 (87.9)
2 27 (81.8) 0 (0) 3 (9.1)
3 5 (15.2) 0 (0) 0 (0)
4 0 (0) 0 (0) 0 (0)
Video 4, bleed rate 0.5 mL/min 366.7 mL/min 176.3 mL/min
0 22 (66.7) 0 (0) 0 (0)
1 10 (30.3) 0 (0) 0 (0)
2 1 (3.0) 0 (0) 1 (3.0)
3 0 (0) 1 (3.0) 12 (36.4)
4 0 (0) 32 (97.0) 20 (60.6)
Video 5, bleed rate 1.3 mL/min 2.9 mL/min 0.2 mL/min
0 0 (0) 0 (0) 29 (87.9)
1 7 (21.2) 12 (36.4) 4 (12.1)
2 24 (72.7) 21 (63.6) 0 (0)
3 2 (6.1) 0 (0) 0 (0)
4 0 (0) 0 (0) 0 (0)
Video 6, bleed rate 5.5 mL/min 15.2 mL/min 9.7 mL/min
0 0 (0) 0 (0) 0 (0)
1 3 (9.1) 0 (0) 0 (0)
2 26 (78.8) 17 (51.5) 1 (3.0)
3 4 (12.1) 16 (48.5) 26 (78.8)
4 0 (0) 0 (0) 6 (18.2)
Video 7, bleed rate 2.7 mL/min 0.2 mL/min 4.0 mL/min
0 0 (0) 29 (87.9) 0 (0)
1 23 (69.7) 4 (12.1) 14 (42.4)
2 10 (30.3) 0 (0) 17 (51.5)
3 0 (0) 0 (0) 2 (6.1)
4 0 (0) 0 (0) 0 (0)
Video 8, bleed rate 366.7 mL/min 46.8 mL/min 40.4 mL/min
0 0 (0) 0 (0) 0 (0)
1 0 (0) 0 (0) 0 (0)
2 0 (0) 1 (3.0) 1 (3.0)
3 0 (0) 22 (66.7) 17 (51.5)
4 33 (100.0) 10 (30.3) 15 (45.5)
Video 9, bleed rate 26.0 mL/min 9.5 mL/min 5.4 mL/min
0 0 (0) 0 (0) 0 (0)
1 1 (3.0) 0 (0) 3 (9.1)
2 15 (45.5) 20 (60.6) 28 (84.9)
3 17 (51.5) 13 (39.4) 2 (6.1)
4 0 (0) 0 (0) 0 (0)
(continued)
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Table III. (continued)
Bleeding severity grade Abdominal cavity videos Pelvic cavity videos Thoracic cavity videos
Video 10, bleed rate 84.8 mL/min 4.5 mL/min 0.1 mL/min
0 0 (0) 0 (0) 5 (15.2)
1 0 (0) 5 (15.2) 28 (84.9)
2 1 (3.0) 26 (78.8) 0 (0)
3 23 (69.7) 2 (6.1) 0 (0)
4 9 (27.3) 0 (0) 0 (0)
The entire response range was used by 33 surgeons assessing 10 unique videos from 3 different surgical cavities. Surgeon responses changed appropriately
with changes in the bleeding severity demonstrating that the scale can detect change. The listed video order represents the order the videos were pre-
sented to surgeons. Data are listed as number of respondents (percent).
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changed appropriately to changes in severity
(Table III).
The average intraobserver agreement for all
surgeons was 0.97 for all types of videos, consti-
tuting “excellent” concordance (Table IV). All Ken-
dall’s W values were >0.7 for each surgeon when
considering all surgical cavity videos (Fig 2). The
overall interobserver agreement among all sur-
geons was 0.89 for all types of videos, constituting
“appreciable” concordance (Table IV).
Surgeons of different surgical specialties repeat-
edly and reproducibly assessed bleeding severities
of their own surgical cavity and of other surgical
cavities. For this reason, videos specific to each
surgical cavity were not required for the validation
phase. The item titled “Intervention” introduced
confusion and differed among the specialties, so it
was removed for the validation phase (Table V).
Validation study phase. A total of 102 surgeons
participated (Table II). The average years of prac-
tice was 14.7 (7.6). All surgeons but one reported
having used hemostatic agents.
All surgeons agreed that the scale can be
implemented for use in a clinical study investi-
gating the efficacy of a hemostatic agent. All
surgeons agreed that the scale was either “very”
(n = 53, 52.0%) or “mostly” (n = 49, 48.0%) self-
explanatory, while none held that it was “not
really” or “not at all” self-explanatory. All surgeons
but one (n = 101, 99.0%) stated that the scale was
relevant for evaluating hemostasis in clinical
studies. Ninety-six surgeons (94.1%) agreed that
the scale reflected the range of bleeding site sizes
and severities expected in clinical practice, while
6 (5.9%) did not. Ninety surgeons (88.2%) agreed
that the scale uses objective terms, while the re-
maining 12 surgeons (11.8%) agreed that the scale
“does not but it does not prevent use.”
Similarly, 82 surgeons (80.4%) agreed that the
scale uses nonoverlapping terms, while the remain-
ing 20 surgeons (19.6%) agreed that the scale“does not but it does not prevent use.” For
surgeons who perform minimally invasive surgery,
79 of 99 (79.8%) stated that the scale can be
applied “as is,” while the remaining 20 (19.6%)
stated that it can be applied “with modification.”
Of the 12 videos presented, 8 were determined to
depict a clinical bleed by 92 or more surgeons
($90.2%), 1 video by 63 surgeons (61.8%), and
the remaining 2 videos were not determined to
depict a clinical bleed. These 2 videos were
assessed as a grade 0 (“No bleeding”), so the
videos were not considered as depicting a bleed
by the majority of surgeons.
The intraobserver agreement among all sur-
geons was 0.98, constituting “excellent” concor-
dance (Table IV). All Kendall’s W values were >0.7
for each surgeon (Fig 2). The overall interobserver
agreement among all surgeons was 0.91, consti-
tuting “excellent” concordance (Table IV).
DISCUSSION
We describe the concept, development, and
validation of a bleeding severity scale for use in
clinical studies to generate labeling claims. The
scale fulfilled all essential criteria required for a
CRS with unanimous agreement to implement it
into clinical studies. The usability, clarity, and
relevance of the scale demonstrate the construct
validity of the scale. And, the intra- and interob-
server agreement demonstrate the reliability (ie,
repeatability and reproducibility) of the scale. As a
result, the scale is a validated means to establish
labeling claims, standardize inclusion and exclu-
sion criteria, and evaluate bleeding severity in
open surgical procedures consistently across all
surgical specialties in clinical studies. This scale
addresses the FDA’s request for a bleeding severity
CRS that is also deemed necessary by surgeons.
In prospective clinical studies investigating
safety and effectiveness of hemostatic agents,
bleeding severity is not defined consistently, and
different levels of bleeding are deemed
Table IV. Feasibility and validation concordance
Kendall’s coefficient of
concordance (Kendall’s W)
Concordance
status
Feasibility phase average intraobserver agreement
All surgeons, all videos (NSurgeons = 33, NVideos = 15) 0.97 Excellent
Abdominal surgeons, all videos (NSurgeons = 12, NVideos = 15) 0.97 Excellent
Pelvic surgeons, all videos (NSurgeons = 11, NVideos = 15) 0.97 Excellent
Thoracic surgeons, all videos (NSurgeons = 10, NVideos = 15) 0.95 Excellent
All surgeons, abdominal videos (NSurgeons = 33, NVideos = 5) 0.98 Excellent
All surgeons, pelvic videos (NSurgeons = 33, NVideos = 5) 0.97 Excellent
All surgeons, thoracic videos (NSurgeons = 33, NVideos = 5) 0.94 Excellent
Feasibility phase interobserver agreement
All surgeons, all videos (NSurgeons = 33, NVideos = 30) 0.89 Appreciable
Abdominal surgeons, all videos (NSurgeons = 12, NVideos = 30) 0.89 Appreciable
Pelvic surgeons, all videos (NSurgeons = 11, NVideos = 30) 0.91 Excellent
Thoracic surgeons, all videos (NSurgeons = 10, NVideos = 30) 0.90 Excellent
All surgeons, abdominal videos (NSurgeons = 33, NVideos = 10) 0.88 Appreciable
All surgeons, pelvic videos (NSurgeons = 33, NVideos = 10) 0.90 Excellent
All surgeons, thoracic videos (NSurgeons = 33, NVideos = 10) 0.88 Appreciable
Validation phase average intraobserver agreement
All surgeons, all videos (NSurgeons = 102, NVideos = 5) 0.98 Excellent
Abdominal surgeons, all videos (NSurgeons = 38, NVideos = 5) 0.98 Excellent
Pelvic surgeons, all videos (NSurgeons = 32, NVideos = 5) 0.98 Excellent
Thoracic surgeons, all videos (NSurgeons = 32, NVideos = 5) 0.98 Excellent
Validation phase interobserver agreement
All surgeons, all videos (NSurgeons = 102, NVideos = 10) 0.91 Excellent
Abdominal surgeons, all videos (NSurgeons = 38, NVideos = 10) 0.93 Excellent
Pelvic surgeons, all videos (NSurgeons = 32, NVideos = 10) 0.92 Excellent
Thoracic surgeons, all videos (NSurgeons = 32, NVideos = 10) 0.88 Appreciable
In the feasibility phase, use of the Bleeding Severity Scale by 33 surgeons achieved “Excellent” intraobserver agreement and “Appreciable” interobserver
agreement. Surgeons assessed 10 unique videos per surgical cavity to determine interobserver agreement and 5 videos twice per surgical cavity to deter-
mine intraobserver agreement. In the validation phase, 102 surgeons achieved “Excellent” concordance status for intraobserver and interobserver agree-
ment. Surgeons assessed 10 unique videos to determine interobserver agreement and 5 videos twice to determine intraobserver agreement. A Kendall’s
coefficient of concordance (Kendall’s W) of 1.0 is “Perfect” agreement.
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definitions used in these studies and the chosen
acceptable level of bleeding for the control agent
are not known to be validated. As a result, the
studies are not comparable and the results cannot
be compared due to the different use of the same
control agent. The use of the developed scale can
be used to establish inclusion and exclusion
criteria appropriate for a control agent to stan-
dardize study designs. Doing so reduces patient
risk of experiencing intraoperative blood loss or
postoperative complications due to hemostatic
agent failure.
In establishing the inclusion and exclusion
criteria, a clinical study can target a specific
bleeding severity level(s) to generate labeling
claims specific to that level of bleeding severity.
Alternatively, a scale can set a defined level of
expected hemostatic performance, such as was
developed for intraoperative surgical staplers.24
The scale developed by Siegel et al24 to evaluatethe efficacy of surgical staplers achieved a Ken-
dall’s W for intraobserver agreement of 0.95 and
interobserver agreement of 0.85 based on 154 sur-
geons. The scale has since been used to evaluate
new surgical staplers.25 While Siegel et al24 demon-
strated reliability of their scale, they did not report
on the validity of their scale (eg, construct validity,
clarity, usability).
In addition to the utility of a validated bleeding
severity scale for use in human clinical studies, the
scale can be used to standardize preclinical animal
models for the development and comparison of
hemostatic agents. The 2 bleeding severity scales
used in animal models are not validated, though
they are considered to be clinically relevant in
scientific literature.26,27 Jackman et al26 designed a
5-point, Likert-type scale to evaluate the efficacy of
harmonic scalpels, where 0 is “no hemostasis” and
4 is “dry.” The scale’s applicability is limited to the
efficacy of harmonic scalpels. Adams et al,27 howev-
er, designed a scale to evaluate the efficacy of
Fig 2. Intraobserver agreement values in the feasibility and validation phase. In the feasibility (top pane) and validation
(bottom pane) phases, all surgeons, collectively and per specialty, achieved a Kendall’s coefficient of correlation (Ken-
dall’s W) > 0.7, indicating that the bleeding severity scale was reliable. No outliers were observed in any of the groups.
Table V. Validated bleeding severity scale
Grade Visual presentation Anatomic appearance Qualitative description
Visually estimated rate of
blood loss (mL/min)
0 No bleeding No bleeding No bleeding #1.0
1 Ooze or intermittent
flow
Capillary-like bleeding Mild >1.0–5.0
2 Continuous flow Venule and arteriolar-
like bleeding
Moderate >5.0–10.0
3 Controllable spurting
and/or overwhelming
flow
Noncentral venous- and
arterial-like bleeding
Severe >10.0–50.0
4 Unidentified or
inaccessible spurting
or gush
Central arterial- or
venous-like bleeding
Life threatening* >50.0
*Systemic resuscitation is required (eg, volume expanders, vasopressors, blood products, etc).
The scale is designed and validated for use in clinical studies to generate labeling claims. The scale is a Likert-type scale, in which the user assigns a grade
based on the overall agreement of the items listed.
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scale of bleeding severity, where 0 is “no bleeding”
and 4 is “severe.” The scale was refined to remove a
“0.5” severity level, which increased its use and
acceptance.28-31This preclinical scale has limited applicability
beyond the lesion type described in these studies.
Outside the use of the validated scale in research
to standardize animal models, the scale can also
provide context for residents and junior faculty
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surgeons who are unclear on when to use which
hemostatic agent.
Strengths. A development process continually
involving surgeons and a validation process
involving surgeons from multiple surgical spe-
cialties are clear strengths. Interestingly, surgeons
do not intuitively understand, interpret, and use
CRSs consistently. The intra- and interobserver
agreement of the scale developed in the concept
phase increased from the feasibility to the valida-
tion phase after changes to the scale. The changes
increased the usability of the scale leading to
unanimous agreement that it can be implemented
into a clinical study. In addition, the scale fulfilled
all FDA criteria for a CRS.
Surgeon assessments detected change appropri-
ately with changes in the known bleeding rate and
used the entire response range. The scale’s reli-
ability was seen within and across surgical spe-
cialties. Reliability was obtained from assessing a
multitude of surgical procedural videos and coa-
gulopathic conditions. A vast majority of surgeons
agreed that the scale was relevant for evaluating
hemostasis and that the range of bleeding site sizes
and severities were appropriately represented.
Limitations. The validation of the scale was
online and used videos depicting various bleeds,
so use in a clinical setting can further support the
scale’s usability. Based on observational data in the
validation phase, it is foreseeable that the scale will
have high usability in the clinical setting. This is
supported by all surgeons determining that the
scale can be implemented for a clinical study and
99.0% of the surgeons determining that the scale is
clinically relevant for evaluating hemostasis. The
usability in the clinical setting may differ if the
videos in the validation were not clinically relevant;
however, all videos depicting an active bleed were
considered to be clinically relevant by surgeons in
the validation phase.
Visual estimations of blood loss are known to be
inaccurate.32-36 As seen in our study and in the
literature, estimations improve after training and
when volumes are generalized to a range.36 Alter-
nate techniques to estimate blood loss from a
bleeding site include gravimetric, colormetric,
photometry, spectrophotometry, and feature
extraction imaging.33,37,38 These traditional tech-
niques have not proven valuable in the clinical
setting due to the need for special equipment,
the availability of staff, or the accuracy of the
technique.
Feature extraction technology, however, is a
recent advancement that measures hemoglobinloss in real time with a high degree of accu-
racy.38-40 Hemoglobin loss, however, does not
represent blood volume loss, which determines
bleeding severity. The applicability of this technol-
ogy is, therefore, limited in its use for determining
bleeding severity.
Future research. In our study, intraobserver
agreement was assessed using a short, test-retest
period. The intraobserver agreement may worsen
with a longer test-retest period. The reliability of
the interobserver agreement in the feasibility and
validation phases, however, demonstrates that sur-
geons use the scale in a consistent way. This
suggests that the intraobserver agreement is not
likely to be affected over long periods of time.
The surgical specialties selected to participate in
this study are those that experience all levels of
bleeding and are typically included in clinical
studies investigating hemostatic agents. Based on
the consistent agreement throughout all study
phases among the included surgical specialties,
the scale is likely to be broadly applicable to all
surgical specialties. Data from the surgical spe-
cialties not included in the development and
validation, however, would be further supportive
of the scale’s broad applicability.
While a majority of surgeons foresee that the
scale is applicable to minimally invasive surgery “as
is,” a follow-up study is warranted to confirm
reliability given the different environment, visibility
(eg, magnification of bleeding, perception of
bleeding), and physiologic effects (eg, hypertension
secondary to insufflation, hypothermia secondary
to nonhumidified or nonwarmed insufflation gases,
decreased venous return, etc).
Further, minimally invasive surgery has a lower
tolerance for blood loss. This may suggest that the
rates of blood loss may need to be revised. Based
on the scale of Siegel et al24 for laparoscopic sta-
plers, surgeons defined hemostasis as an oozing
bleed that progresses for 15 seconds but does not
require intervention. In comparison, this defini-
tion aligns to grade 0 “no bleeding” with a rate
of blood loss of <1.0 mL/min. This suggests that
the visually estimated rates of blood loss are trans-
latable to minimally invasive surgery.
In conclusion, we document the development
and validation of an intraoperative bleeding
severity scale that fulfills FDA criteria for a CRS.
This validated scale is an essential tool for use in
clinical studies to standardize inclusion-exclusion
criteria and to assess the performance of hemo-
static agents in clinical studies of hemostatic
agents. The scale is designed to generate labeling
claims that are clinically relevant, which can
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hemostatic agent for the right bleed, ultimately
reducing intraoperative and postoperative
bleeding complications.
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